CN113317864A - Cell irreversible electroporation device and cell irreversible electroporation method - Google Patents
Cell irreversible electroporation device and cell irreversible electroporation method Download PDFInfo
- Publication number
- CN113317864A CN113317864A CN202010133690.3A CN202010133690A CN113317864A CN 113317864 A CN113317864 A CN 113317864A CN 202010133690 A CN202010133690 A CN 202010133690A CN 113317864 A CN113317864 A CN 113317864A
- Authority
- CN
- China
- Prior art keywords
- electroporation
- conductive needle
- cavity
- cell
- irreversible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004520 electroporation Methods 0.000 title claims abstract description 106
- 230000002427 irreversible effect Effects 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 73
- 230000007246 mechanism Effects 0.000 claims abstract description 71
- 230000005684 electric field Effects 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims description 47
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 47
- 210000004027 cell Anatomy 0.000 abstract description 37
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 abstract description 13
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000005909 tumor killing Effects 0.000 abstract description 3
- 238000009434 installation Methods 0.000 description 11
- 230000001052 transient effect Effects 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 9
- 230000002147 killing effect Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00613—Irreversible electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1425—Needle
- A61B2018/1427—Needle with a beveled end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1425—Needle
- A61B2018/143—Needle multiple needles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Electrotherapy Devices (AREA)
Abstract
The invention provides a cell irreversible electroporation device, which comprises an electroporation mechanism, a first electroporation mechanism and a second electroporation mechanism, wherein the electroporation mechanism comprises at least two conductive needle bodies, each conductive needle body is provided with a first cavity, and a first opening and a second opening which are used for communicating the first cavity with the outside; the medicine supply mechanism is connected with the conductive needle body and used for conveying medicine molecules to the first cavity of the conductive needle body; and the power supply assembly is connected with the electroporation mechanism and is used for providing an electric field for irreversible electroporation of the cells to the electroporation mechanism. The cell electroporation device combines the anti-cancer drugs with the locally applied irreversible electroporation electric field, can realize the efficient killing of tumor cells, effectively improves the tumor treatment effect, further reduces the dosage of the anti-cancer drugs, lightens the toxic and side effects of the anti-cancer drugs on the body, and has better application prospect in the field of cancer treatment.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a cell irreversible electroporation device and a cell irreversible electroporation method.
Background
Tumor is a disease seriously threatening human health, is formed by continuous excessive hyperplasia of cells, and has the characteristics of invading peripheral tissues and transferring to other organs. The tumor seriously harms the human health and is one of the public health problems recognized in the world today. At present, the treatment method of tumor mainly comprises operation treatment, radiotherapy, chemotherapy, immunotherapy and the like. The chemotherapy is to treat tumors by using chemical drugs capable of killing tumor cells, and part of drug molecules reach the focus of infection through the internal circulation of the body by oral administration, intramuscular injection or intravenous injection so as to kill cancer cells.
Chemotherapy allows the drug to reach the focus through internal circulation, and the drug is also absorbed by normal tissues of the body during the internal circulation process, resulting in toxic and side effects of the drug. In addition, the quality of the chemotherapy effect is related to the dosage of the medicine. However, the application of large dose of medicine can increase the toxic and side effects of the medicine. The pulse electric field is used to make tumor cell produce electroporation, raise cell membrane permeability, promote medicine to enter cell interior and raise medicine curative effect so as to attain the goal of curing tumor. The electrochemotherapy reduces the permeability disorder of the medicament by applying an electric field to form electroporation on a tumor cell membrane, and is beneficial to improving the medicament absorption efficiency and reducing the toxic and side effects of the medicament. However, because the electrochemical therapy forms transient perforation on the tumor cell membrane, the transient perforation disappears after several hours, the long-acting absorption of the tumor drug cannot be formed, and the killing effect on the tumor cells is limited. In addition, the electroporation is beneficial to reducing the dosage of the medicine, but the medicine still reaches normal tissues through internal circulation during the use process, and causes higher toxic and side effects on the normal tissues.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to overcome the defects that the tumor cells cannot absorb the drug for a long time in the prior art when the tumor is treated by the electrochemical therapy, so that the killing effect on the tumor cells is limited and the toxic and side effects of normal tissues are caused.
Therefore, the invention provides the following technical scheme:
in a first aspect, the present invention provides a cell irreversible electroporation apparatus comprising:
the electroporation mechanism comprises at least two conductive needle bodies, wherein each conductive needle body is provided with a first cavity, a first opening and a second opening, and the first openings and the second openings are used for communicating the first cavities with the outside;
the medicine supply mechanism is connected with the conductive needle body and used for conveying medicine molecules to the first cavity of the conductive needle body;
and the power supply assembly is connected with the electroporation mechanism and is used for providing an electric field for irreversible electroporation of the cells to the electroporation mechanism.
Alternatively, in the above-described irreversible electroporation apparatus for cells, the power supply mechanism may apply a pulsed electric field having a positive and negative bipolarity to the electroporation mechanism.
Further optionally, in the irreversible electroporation apparatus for cells described above, the electric field strength of the pulsed electric field is not less than 500V/cm, the pulse frequency is not less than 5kHz, and the pulse width is 0.1-100. mu.s.
Optionally, in the irreversible cell electroporation apparatus described above, the power supply mechanism includes a pulsed electric field generator, and a lead connecting the pulsed electric field generator and the electroporation mechanism.
Optionally, in the irreversible cell electroporation apparatus described above, the first cavity forms a connection end and a piercing end at two ends of the conductive needle body that are relatively far away from each other, the second opening is formed at the connection end, and the first opening is formed at the piercing end.
Further optionally, in the irreversible cell electroporation apparatus described above, the first cavity extends axially inside the needle body, the piercing end has an end surface inclined toward the first cavity, and the first opening is located on the end surface.
Optionally, the above-mentioned irreversible cell electroporation device further comprises a base having an installation inner cavity, the conductive needle is slidably disposed in the base, and the first opening of the conductive needle can penetrate out of the installation inner cavity.
Optionally, in the irreversible cell electroporation apparatus described above, an expansion mechanism is further disposed in the installation inner cavity of the base, two ends of the expansion mechanism respectively abut against the bottom inner surface of the base and the conductive needle body, and the expansion mechanism drives the conductive needle body to move in a direction away from or close to the base.
Optionally, in the irreversible cell electroporation apparatus described above, the drug delivery mechanism includes a storage component for storing drug molecules, a conduit for communicating the storage component with the conductive needle, and a driving component for driving the drug molecules to circulate in the conduit.
In a second aspect, the present invention provides a cell perforation method using the above-described cell irreversible electroporation apparatus.
The technical scheme of the invention has the following advantages:
1. the invention provides a cell irreversible electroporation device, an electroporation mechanism comprises at least two conductive needle bodies, wherein each conductive needle body is provided with a first cavity, a first opening and a second opening, and the first opening and the second opening are used for communicating the first cavity with the outside; the medicine supply mechanism is connected with the conductive needle body and used for conveying medicine molecules to the first cavity of the conductive needle body; and the power supply assembly is connected with the electroporation mechanism and is used for providing an electric field for irreversible electroporation of the cells to the electroporation mechanism.
In the above-mentioned irreversible electroporation apparatus for cells, the needle of the electroporation mechanism is inserted into a target tissue region (for example, tumor tissue), and the power supply mechanism connected to the electroporation mechanism applies an electric field for irreversible electroporation of cells to the target tissue region through the conductive needle, so that irreversible electroporation is generated on the cell membrane of the tumor cells, thereby inducing necrosis and apoptosis of the tumor cells. Meanwhile, the medicine supply mechanism is connected with the first cavity of the conductive needle body, medicine molecules are conveyed to the first cavity by the medicine supply mechanism, and the medicine molecules are delivered to the tumor cell accessory subjected to electroporation through the conductive needle body and enter the tumor cells through the electroporation, so that the tumor cells are killed and killed in a targeted manner. In the prior art, the electrochemical therapy improves the permeability of cell membranes and reduces the permeability disorder of tumor cells to drugs by forming transient perforations on the tumor cells. However, transient perforation has a short duration, and cannot form long-term absorption of anticancer drugs by tumor cells, thereby limiting the killing effect on tumor cells and the relative dose reduction of anticancer drugs. The irreversible electroporation device for the cells can form long-acting receiving on drug molecules and improve the killing effect of the drug molecules on the tumor cells compared with transient electroporation by forming irreversible electroporation on cell membranes of the tumor cells. Because the irreversible electroporation relatively improves the efficiency of the drug molecules entering the tumor cells, compared with the method of promoting the drug molecules to enter the tumor cells by transient electroporation, the method is beneficial to reducing the dosage of the tumor drug molecules and further reducing the toxic and side effects of the drug molecules on normal tissues of a body. In addition, because the conductive needle body of the electroporation mechanism is inserted into the vicinity of the tumor tissue in a targeted manner, the drug molecules directly enter the tumor cells at the tumor tissue attachment through electroporation on the cell membrane, and the side effects of the drug caused by entering the normal tissues of the body through the internal circulation of the body are avoided.
The cell electroporation device combines the anti-cancer drugs with the locally applied irreversible electroporation electric field, can realize the efficient killing of tumor cells, effectively improves the tumor treatment effect, further reduces the dosage of the anti-cancer drugs, lightens the toxic and side effects of the anti-cancer drugs on the body, and has better application prospect in the field of cancer treatment.
2. According to the irreversible cell electroporation device provided by the invention, the power supply mechanism applies a positive and negative bipolar pulse electric field to the electroporation mechanism, the electric field strength of the pulse electric field is more than or equal to 500V/cm, the pulse frequency is more than or equal to 5kHz, and the pulse width is 0.1-100 mus. By setting the electric field parameters, irreversible electroporation on tumor cells can be achieved and damage to normal tissue is minimized.
3. According to the irreversible cell electroporation device provided by the invention, the first cavity forms the connecting end and the piercing end at the two ends of the conductive needle body which are relatively far away, the second opening is formed at the connecting end, and the first opening is formed at the piercing end. The cell irreversible electroporation device penetrates into tumor tissue through the penetrating end of the conductive needle body, medicine molecules in the medicine supply mechanism enter a first cavity of the conductive needle body through a second opening of the connecting end, then are conveyed to the tumor tissue through the first opening by the conveying of the first cavity, and the medicine molecules enter the tumor cell through irreversible electroporation on the tumor cell to kill the tumor cell.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a schematic structural view of a cell irreversible electroporation apparatus provided in example 1 of the present invention;
fig. 2 is a schematic structural view of a conductive pin body provided in embodiment 1 of the present invention;
fig. 3 is a schematic view of a conductive needle provided in example 1 of the present invention penetrating into tumor tissue;
description of reference numerals:
1-an electroporation mechanism, 11-a conductive needle body, 12-a base, 13-a telescopic mechanism, 111-a first opening, 112-a second opening, 113-a first cavity, 114-a puncture end and 115-a connecting end;
2-supply mechanism, 21-storage, 22-pipeline, 23-driving piece;
3-power supply mechanism, 31-pulse electric field generating piece, 32-wire.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the accompanying drawings, and it should be understood that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, and are only for convenience of description and simplicity of description, but do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, should not be construed as limiting the present invention. Furthermore, the terms "first," "second," and "third" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.
In the description of the present invention, it should be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, e.g., as meaning either a fixed connection, a removable connection, or an integral connection; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in specific cases to those skilled in the art.
In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
The present embodiment provides a cell irreversible electroporation apparatus, as shown in FIG. 1, comprising an electroporation mechanism 1, a drug supply mechanism 2, and a power supply mechanism 3.
As shown in fig. 1 and 2, the electroporation mechanism 1 includes at least two conductive needle bodies 11, a base 12, and a retracting mechanism 13. The base 12 is provided with an installation inner cavity and an opening communicated with the installation inner cavity and the outside, the telescopic mechanism 13 is arranged in the installation inner cavity of the base 12, two ends of the telescopic mechanism 13 are respectively abutted against the inner surface of the bottom of the base 12 and the conductive needle body 11, and the conductive needle body 11 can be slidably arranged in the installation inner cavity of the base 12 through the reciprocating motion of the telescopic mechanism 13 in the installation inner cavity of the base 12. The telescopic mechanism 13 drives the conductive needle body 11 to move towards the direction far away from or close to the base 12, and when the conductive needle body 11 moves towards the direction far away from the base 12, the conductive needle body can penetrate out of the installation inner cavity, and the penetrated end of the conductive needle body is convenient to penetrate into the position near tumor tissue. After the puncture process is completed, the conductive needle body 11 can be moved toward the direction close to the base 12, and the conductive needle body 11 can be retracted into the mounting cavity. The number of the conductive needle bodies 11 can be 2, 3, 4, etc., and the conductive needle bodies 11 can be arranged according to actual needs as long as the conductive needle bodies 11 can transmit an electric field with uniform distribution to tumor tissues after penetrating the tumor tissues.
Specifically, as shown in fig. 2, the conductive pin body 11 has a first cavity 113, and a first opening 111 and a second opening 112 that connect the first cavity 113 with the outside, the first cavity 113 extends along the circumferential direction of the conductive pin body 11, and a connection end 115 and a piercing end 114 are formed at two ends of the conductive pin body 11 that are relatively far away. Wherein, the piercing end 114 has an end surface inclined toward the first cavity 113, so as to facilitate the piercing injection of the conductive needle body 11 into the tissue. The piercing end 114 of the conductive needle body 11 is formed with a first opening 111, and the connection end 115 is formed with a second opening 112. When the conductive needle body 11 is used to deliver drug molecules, the conductive needle body 11 moves away from the installation cavity under the driving of the telescopic mechanism 13, and the piercing end 114 of the conductive needle body 11 penetrates out of the installation cavity and pierces into the inside of the tissue. The drug molecules enter the first cavity 113 of the conductive needle body 11 through the second opening 112 of the connection end 115, and are finally delivered to the target tissue region through the first opening 111 of the piercing end 114 after circulating in the first cavity 113.
The power supply means 3 is connected to the electroporation means 1 and applies an electric field for irreversibly electroporating the cells to the electroporation means 1. Specifically, as shown in fig. 1, the power supply mechanism 3 includes a pulsed electric field generating member 31 for supplying a pulsed electric field, and a lead wire 32 connecting the pulsed electric field generating member 31 and the electroporation mechanism 1. The pulse electric field generator 31 is specifically a pulse generator selected according to actual needs, and the pulse generator is used for providing a pulse electric field with positive and negative polarities to the electroporation mechanism 1, and parameters of the pulse electric field are as follows: the electric field intensity was 500V/cm, the pulse frequency was 5kHz, and the pulse width was 0.1. mu.s. With a pulsed electric field of the above parameters, irreversible electroporation on tumor cells can be achieved and damage to normal tissues is minimized. As a variant, the parameters of the pulse electric field can be any one of the parameters of electric field intensity more than or equal to 500V/cm, pulse frequency more than or equal to 5kHz and pulse width in the range of 0.1-100 mu s, and can realize the non-electroporation of the tumor cells
The drug supply mechanism 2 is connected with the conductive needle body 11 of the electroporation mechanism 1 and is used for delivering drug molecules to the first cavity 113 of the conductive needle body 11. As shown in fig. 1, the drug delivery mechanism 2 includes a storage 21 for storing drug molecules, a conduit 22 for communicating the storage 21 with the conductive needle 11, and a driving member 23 for driving the drug molecules to flow through the conduit 22. Specifically, the driving member 23 may be a peristaltic pump or the like capable of driving the liquid to flow in the tube 22, the peristaltic pump having an inlet end and an outlet end of the tube 22, the tube 22 entering the peristaltic pump from the inlet end and then exiting from the outlet end, and then being connected to the electroporation mechanism 1. Drug molecules are delivered from the reservoir 21 to the electroporation mechanism 1 by actuation of the peristaltic pump. In the electroporation structure, the tube 22 for delivering drug molecules is communicated with the first cavity 113 of the conductive needle 11 through the second opening 112 of the conductive needle 11, so that the drug molecules are delivered into the first cavity 113 and finally output through the first opening 111 of the conductive needle 11, so that the drug molecules are delivered to the vicinity of tumor tissue. The drug molecules enter the tumor cells through irreversible electroporation on the tumor cells to kill the tumor cells.
When the cell irreversible electroporation device is used for treating tumors, the specific process is as follows: as shown in FIG. 3, when the conductive needle body 11 of the electroporation mechanism 1 is driven by the retracting mechanism 13, the piercing end 114 of the conductive needle body 11 protrudes from the mounting cavity of the base 12 of the electroporation mechanism 1, and the conductive needle body penetrates into the tumor tissue region of the target through the inclined end surface of the piercing end 114. The pulse generator of the power supply mechanism 3 is utilized to provide a pulse electric field with required parameters to the conductive needle body 11, and the pulse electric field is applied to a tumor tissue region through the conductive needle body 11, so that irreversible electroporation is generated on the cell membrane of tumor cells, and the necrosis and the apoptosis of the tumor cells are induced. Meanwhile, under the driving action of the driving part 23 of the drug supply mechanism 2, the drug molecules in the storage part 21 of the drug supply mechanism 2 enter the first cavity 113 of the conductive needle body 11 through the pipeline 22, and are discharged from the first opening 111 of the conductive needle body 11 after being transported in the first cavity 113, so that the drug molecules are delivered to the vicinity of the tumor cells where electroporation is performed, and enter the tumor cells through electroporation, and the tumor cells are killed and killed in a targeted manner. In the prior art, the electrochemical therapy improves the permeability of cell membranes and reduces the permeability disorder of tumor cells to drugs by forming transient perforations on the tumor cells. However, transient perforation has a short duration, and cannot form long-term absorption of anticancer drugs by tumor cells, thereby limiting the killing effect on tumor cells and the relative dose reduction of anticancer drugs. The irreversible electroporation device for the cells can form long-acting receiving on drug molecules and improve the killing effect of the drug molecules on the tumor cells compared with transient electroporation by forming irreversible electroporation on cell membranes of the tumor cells. Because the irreversible electroporation relatively improves the efficiency of the drug molecules entering the tumor cells, compared with the method of promoting the drug molecules to enter the tumor cells by transient electroporation, the method is beneficial to reducing the dosage of the tumor drug molecules and further reducing the toxic and side effects of the drug molecules on normal tissues of a body. In addition, because the conductive needle body 11 of the electroporation mechanism 1 is penetrated into the vicinity of the tumor tissue in a targeted manner, drug molecules directly enter tumor cells through electroporation on cell membranes in the vicinity of the tumor tissue, and the side effects of the drugs caused by the drug molecules entering normal tissues of the body through the internal circulation of the body are avoided.
The cell electroporation device combines the anti-cancer drugs with the locally applied irreversible electroporation electric field, can realize the efficient killing of tumor cells, further reduces the dosage of the anti-cancer drugs, lightens the toxic and side effects of the anti-cancer drugs on bodies, and has better application prospect in the field of cancer treatment.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (10)
1. An irreversible electroporation apparatus for a cell, comprising:
the electroporation mechanism (1) comprises at least two conductive needle bodies (11), wherein each conductive needle body (11) is provided with a first cavity (113), and a first opening (111) and a second opening (112) which are used for communicating the first cavity (113) with the outside;
the medicine supply mechanism (2), the medicine supply mechanism (2) is connected with the conductive needle body (11), and is used for conveying medicine molecules to the first cavity (113) of the conductive needle body (11);
the power supply mechanism (3) is connected with the electroporation mechanism (1) and is used for providing an electric field for irreversible electroporation of the cells to the electroporation mechanism (1).
2. The cell irreversible electroporation apparatus according to claim 1, wherein the power supply means (3) applies a pulsed electric field having positive and negative bipolarity to the electroporation means (1).
3. The irreversible electroporation apparatus for cells according to claim 2, wherein the electric field strength of the pulsed electric field is not less than 500V/cm, the pulse frequency is not less than 5kHz, and the pulse width is 0.1 to 100. mu.s.
4. The irreversible cell electroporation apparatus according to any one of claims 1 to 3, wherein the power supply means (3) comprises a pulsed electric field generating member (31), and a lead wire (32) connecting the pulsed electric field generating member (31) and the electroporation means (1).
5. The irreversible cell electroporation device according to any one of claims 1 to 4, wherein the first cavity (113) forms a connection end (115) and a piercing end (114) at both ends of the conductive needle body (11) relatively far away, the second opening (112) is formed at the connection end (115), and the first opening (111) is formed at the piercing end (114).
6. The device according to claim 5, characterized in that said first cavity (113) extends axially inside said needle, said piercing end (114) having an end face inclined towards said first cavity (113), said first opening (111) being located on said end face.
7. The device according to any one of claims 1 to 6, further comprising a base (12) having a mounting lumen, wherein the conductive needle (11) is slidably disposed in the base (12), and the first opening (111) of the conductive needle (11) can pass through the mounting lumen.
8. The irreversible cell electroporation device according to claim 7, wherein a telescopic mechanism (13) is further disposed in the mounting inner cavity of the base (12), two ends of the telescopic mechanism (13) respectively abut against the bottom inner surface of the base (12) and the conductive needle body (11), and the telescopic mechanism (13) drives the conductive needle body (11) to move in a direction away from or close to the base (12).
9. The device according to any one of claims 1 to 8, wherein the drug supply mechanism (2) comprises a reservoir (21) for storing drug molecules, a channel (22) for communicating the reservoir (21) with the conductive needle (11), and a driving member (23) for driving the drug molecules to flow through the channel (22).
10. A cell perforation method using the cell irreversible electroporation apparatus according to any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010133690.3A CN113317864A (en) | 2020-02-28 | 2020-02-28 | Cell irreversible electroporation device and cell irreversible electroporation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010133690.3A CN113317864A (en) | 2020-02-28 | 2020-02-28 | Cell irreversible electroporation device and cell irreversible electroporation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113317864A true CN113317864A (en) | 2021-08-31 |
Family
ID=77412895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010133690.3A Pending CN113317864A (en) | 2020-02-28 | 2020-02-28 | Cell irreversible electroporation device and cell irreversible electroporation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113317864A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN204147418U (en) * | 2014-03-18 | 2015-02-11 | 苏州壹达生物科技有限公司 | A kind of device utilizing the administration of coreless armature pin electroporation |
| CN106388932A (en) * | 2016-07-12 | 2017-02-15 | 上海睿刀医疗科技有限公司 | Irreversible electroporation equipment |
-
2020
- 2020-02-28 CN CN202010133690.3A patent/CN113317864A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN204147418U (en) * | 2014-03-18 | 2015-02-11 | 苏州壹达生物科技有限公司 | A kind of device utilizing the administration of coreless armature pin electroporation |
| CN106388932A (en) * | 2016-07-12 | 2017-02-15 | 上海睿刀医疗科技有限公司 | Irreversible electroporation equipment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7967763B2 (en) | Method for treating subcutaneous tissues | |
| US20070060989A1 (en) | Apparatus and method for disrupting subcutaneous structures | |
| KR101529448B1 (en) | Device for treating microscopic residual tumors remaining in tissues following surgical resection | |
| JP4899020B2 (en) | Device for use in preventive treatment or therapy of tissue | |
| US20150297887A1 (en) | Electroporation device | |
| EP3254725B1 (en) | Apparatus for treating blood vessels in skin | |
| US20100174340A1 (en) | Methods and Apparatus for Applying Energy to Patients | |
| WO2004037341A2 (en) | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy | |
| CN108704218A (en) | A kind of painless dosing paster of skin | |
| EP2265204B1 (en) | Device comprising an enclosure and an interior electrode for delivering energy to a mammal | |
| CN113317864A (en) | Cell irreversible electroporation device and cell irreversible electroporation method | |
| Sersa et al. | Electrochemotherapy of solid tumors—preclinical and clinical experience | |
| US9242041B2 (en) | Method and apparatus for cancer treatment | |
| Hui et al. | Enhancing transdermal drug delivery with electroporation | |
| KR101200249B1 (en) | Transdermal drug delivery device | |
| CN103520831A (en) | Liquid medicine ultrasonic therapy circulatory system | |
| Евстифеев et al. | Фотодинамическая терапия больных раком нижней губы | |
| CN118320281A (en) | Gastrointestinal tract expander for microneedle drug-loaded photodynamic therapy and application method thereof | |
| RU78659U1 (en) | INSTALLATION AND DEVICE FOR TREATMENT OF TUMOR DISEASES | |
| CN115591103A (en) | Miniature patch type ultrasonic microneedle array for skin anesthesia | |
| WO2010006483A1 (en) | An apparatus of low strength electric field network-mediated delivery of drug to target cell of liver | |
| CN113813494A (en) | Body fluid transfer device and body fluid transfer method | |
| Tozon et al. | Electrochemotherapy in veterinary medicine | |
| HRP20020790A2 (en) | Directional system of coordinated electro and ultrasound poring for administering medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |
|
| RJ01 | Rejection of invention patent application after publication |